Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.68)
# 749
Out of 5,156 analysts
81
Total ratings
59.7%
Success rate
26.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $22.61 | +50.38% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $58.78 | +25.89% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $460.87 | +15.00% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $13.89 | -13.61% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $323.59 | +59.17% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.43 | -63.17% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $28.98 | +55.28% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.62 | +39.21% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.32 | +115.52% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $46.74 | -25.12% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $433.20 | -16.90% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $5.25 | -61.90% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.88 | +544.33% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.67 | +517.28% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $38.97 | -38.41% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $14.00 | +114.29% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.72 | +111.86% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $22.61
Upside: +50.38%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $58.78
Upside: +25.89%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $460.87
Upside: +15.00%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $13.89
Upside: -13.61%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $323.59
Upside: +59.17%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.43
Upside: -63.17%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $28.98
Upside: +55.28%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.62
Upside: +39.21%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.32
Upside: +115.52%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $46.74
Upside: -25.12%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $433.20
Upside: -16.90%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $5.25
Upside: -61.90%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.88
Upside: +544.33%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.67
Upside: +517.28%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $38.97
Upside: -38.41%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $14.00
Upside: +114.29%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.72
Upside: +111.86%